NeutriSci Announces Initial Order From Cryopharm

NeutriSci International Inc. (the “Company” or “NeutriSci”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy, is pleased to announce that it has received an initial order from Cryopharm Corporation (“Cryopharm”).

NeutriSci and Thai Freeze Dry Join Forces to Develop New Product Line of Cannabis Edibles

NeutriSci International Inc. (the “Company” or “NeutriSci”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy, and Thai Freeze Dry Co. Ltd. (“TFD”) are pleased to announce they have entered into a Letter of Intent (“LOI”) to develop and sell a line of products that incorporate both companies’ IP and technology for enhancing palatability and bioavailability of beneficial molecules including, but not limited to, cannabinoids, into NeutriSci’s existing and pipeline product formats.

Neutrisci Announces Product Sales Increase

Neutrisci International Inc. (the “Company” or “NeutriSci”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy, is pleased to announce that it has received its first order for its sublingual cannabidiol (CBD) tablets. This initial order will result in the Company reporting six figure sales for the current quarter. The quick dissolving, flavoured tablets are manufactured using the Company’s patent pending technology and offer a method to provide the consumer with a measured dose of known CBD product.

NeutriSci Announces Exclusive Licensing Agreement for CBD Tablet Manufacturing & Distribution With LaSanta Botanicals Ltd.

NeutriSci International Inc. (the “Company” or “NeutriSci”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy, is pleased to announce that it has entered into a Memorandum of Understanding (“MOU”) outlining the terms for the manufacturing & distribution of sub-lingual CBD tablets, based on NeutriSci’s proprietary sublingual tablet formulations, with LaSanta Botanicals Ltd., a privately held company based in Calgary, Alberta, with operations in Bogota, Colombia (the “Licensee”). The Licensee is licensed in Colombia to cultivate cannabis and to manufacture and export cannabis extracts.

Nutritional High and NeutriSci International to Launch Cannabis-Infused Tablets July 11th

NeutriSci International Inc. (“NeutriSci”) (TSX-V:NU) (OTCQB:NRXCF) (FRANKFURT:1N9) the innovator and pioneer behind neuenergy(R) is pleased to provide an update on its previously announced partnership with Nutritional High International Inc. (the “Company” or “Nutritional High”) (CSE:EAT) (OTCQB:SPLIF) (FRANKFURT:2NU) (see press release dated May 30, 2018).

NeutriSci Provides Update on Patent Pending Technology

NeutriSci International Inc. (“NeutriSci”) (TSX-V:NU) (OTCQB:NRXCF) (FRANKFURT:1N9) the innovator and pioneer behind neuenergy, is pleased to announce advancements with its patent pending technology, trade named “Cryolisation”.

NeutriSci and Nutritional High Enter Into Agreement to Develop, Manufacture & Distribute Cannabis Infused Products

NeutriSci International Inc. (“NeutriSci”) (TSX-V:NU) (OTCQB:NRXCF) (FRANKFURT:1N9) the innovator and pioneer behind neuenergy, and Nutritional High International Inc. (“Nutritional High) (CSE:EAT) (OTCQB:SPLIF) (FRANKFURT:2NU), are pleased to announce the entry into a binding Memorandum of Understanding (“MOU”) to develop, manufacture and distribute THC and CBD infused sublingual tablets utilizing NeutriSci’s patent pending technology, proprietary ingredients and formulations.